Skip to Content
Merck
CN

Key Documents

View All Documentation

B3303

Buserelin acetate salt

≥90% (HPLC)

Synonym(s):

des-Gly10-[D-Ser[t-Bu]6]-LH-RH ethylamide acetate salt, pGlu-His-Trp-Ser-Tyr-D-Ser(t-Bu)-Leu-Arg-Pro-NHEt acetate salt

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C60H86N16O13 · C2H4O2
CAS Number:
68630-75-1
Molecular Weight:
1299.48
UNSPSC Code:
51111800
NACRES:
NA.32
MDL number:
MFCD00941414
Form:
powder
Assay:
≥90% (HPLC)
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

200

assay

≥90% (HPLC)

form

powder

UniProt accession no.

P12391

storage temp.

−20°C

SMILES string

[nH]1cncc1C[C@H](NC(=O)[C@H]6NC(=O)CC6)C(=O)N[C@@H](Cc4c5c([nH]c4)cccc5)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3ccc(cc3)O)C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N2[C@@H](CCC2)C(=O)NCC.OC(=O)C

InChI

1S/C60H86N16O13.C2H4O2/c1-7-64-57(87)48-15-11-23-76(48)58(88)41(14-10-22-65-59(61)62)69-51(81)42(24-33(2)3)70-56(86)47(31-89-60(4,5)6)75-52(82)43(25-34-16-18-37(78)19-17-34)71-55(85)46(30-77)74-53(83)44(26-35-28-66-39-13-9-8-12-38(35)39)72-54(84)45(27-36-29-63-32-67-36)73-50(80)40-20-21-49(79)68-40;1-2(3)4/h8-9,12-13,16-19,28-29,32-33,40-48,66,77-78H,7,10-11,14-15,20-27,30-31H2,1-6H3,(H,63,67)(H,64,87)(H,68,79)(H,69,81)(H,70,86)(H,71,85)(H,72,84)(H,73,80)(H,74,83)(H,75,82)(H4,61,62,65);1H3,(H,3,4)/t40-,41-,42-,43-,44-,45-,46-,47+,48-;/m0./s1

InChI key

PYMDEDHDQYLBRT-DRIHCAFSSA-N

Gene Information

rat ... Chrnb3(171131)

Biochem/physiol Actions

Buserelin is an LH-RH agonist.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

hcodes

H302,H360

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Regulatory Information

监管及禁止进口产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCK3361
BCCF7047
BCBZ3987
BCBV1707
BCBD9630V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Christoph Gerlinger et al.
BMC women's health, 12, 9-9 (2012-04-21)
Approaches to the treatment of endometriosis vary worldwide, but studies comparing endometriosis medications in different ethnic groups are rare. A systematic literature search identified two studies directly comparing dienogest (DNG) versus gonadotropin-releasing hormone (GnRH) analogues in European and Japanese populations.
Mari Kasai et al.
Fertility and sterility, 98(2), 440-443 (2012-07-04)
To determine correlations between shrinkage of uterine leiomyomas after treatment with GnRH agonists (GnRH-a) or menopause and expression levels of estrogen receptors (ER), progesterone receptors (PR), and vascular endothelial growth factor (VEGF). Cohort study. University teaching hospital. A total of
S Zhao et al.
Gynecologic and obstetric investigation, 49(1), 52-56 (2000-01-12)
Gonadotropin-releasing hormone (GnRH) has been found to be expressed in ovaries of various species and to modulate cell differentiation in ovarian cells. GnRH agonists (GnRHa) are widely used in the stimulation protocols of assisted reproduction. In the present study, the
Tom Pickles et al.
BJU international, 110(11 Pt B), E500-E507 (2012-05-09)
What's known on the subject? and What does the study add? Previous reports, with small numbers of patients, have described the problem of incomplete testosterone suppression (>1.1 or 1.7 nmol/L) with LHRH agonists. Various predisposing factors have been suggested: different
Elin Sand et al.
Cell and tissue research, 351(3), 521-534 (2012-12-21)
Gonadotropin-releasing hormone (GnRH) analogs are given to women undergoing in vitro fertilization. Case reports describing the development of chronic intestinal pseudo-obstruction and auto-antibodies against GnRH after such treatment suggest a strong association between intestinal dysfunction and GnRH analogs. No experimental
View All Related Papers

Global Trade Item Number

SKUGTIN
B3303-1MG04061833427644

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service